Cite
HARVARD Citation
Bordi, P. et al. (2019). From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC. Lung cancer. pp. 78-85. [Online].